Keyword: Inovio

Gilead continues revamp with 3 more exec exits; GSK snares ex-Novartis, AZ CFO as chairman; and Immusoft names former Amgen biologics head as CSO.

Inovio Pharmaceuticals is cutting 28% of its workforce and swinging the ax to a bladder cancer test.

AstraZeneca is starting to look at cutting some of the fat from its external pacts, and Inovio is in the crosshairs.

Inovio spinout Geneos goes independent with a $10.5 million first-round financing for R&D in neoantigen-targeting cancer immunotherapies.

New biotech discoveries include CRISPR-induced conception and a biomarker for predicting breast cancer recurrences.

Sensei Biotherapeutics named Ildiko Csiki as CMO. Csiki was previously VP of immuno-oncology clinical development at Inovio Pharmaceuticals.

Teva’s former chairman Peterburg resigns, OrbiMed founder Isaly steps down, Grail poaches Roche exec Cook as CEO.

A Stanford team aimed at host cells to fight flaviviruses, while Harvard scientists examined the longevity of Zika vaccines.

A synthetic DNA vaccine developed by the Wistar Institute and Penn scientists, with support from Inovio and GeneOne, shows promise in human trials.

A pair of experimental vaccines protected mouse fetuses from brain defects caused by Zika infection.